Bain Capital Life Sciences Fund III
Managed by Bain Capital
Overview
Bain Capital Life Sciences Fund III is part of Bain Capital’s life sciences platform, with exposure to biopharmaceutical and medical technology companies through affiliated investment vehicles. Named holdings include companies developing cell therapies, autoimmune-disease treatments and non-invasive cardiovascular technology.
Bain Capital Life Sciences, a Bain Capital business established in 2016, invests globally across biopharmaceuticals, medical devices, diagnostics and life science tools. Its team combines private- and public-market investing experience with operating, consulting, scientific and medical expertise. The platform invests in clinical- and commercial-stage companies and provides strategic support around key development and commercialization phases.
Selected investments
- Heartflow — Developer of non-invasive cardiovascular technology used to assess coronary artery disease.
- Kyverna Therapeutics — Clinical-stage biotechnology company developing cell therapies for autoimmune diseases.
- Cabaletta Bio — Clinical-stage biotechnology company developing cell therapies for autoimmune diseases.
- Century Therapeutics — Biotechnology company developing allogeneic cell therapies.
Acquire an interest in Bain Capital Life Sciences Fund III
You might be able to acquire a position in Bain Capital Life Sciences Fund III. Sign up to explore available positions.
Gauge buyer interest for Bain Capital Life Sciences Fund III
Sign up here to anonymously gauge interest in your Bain Capital Life Sciences Fund III position.
Do you manage this fund? Get in touch to edit the text here.